Singapore markets close in 5 hours 22 minutes

Kyowa Kirin Co., Ltd. (KYKOF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
17.000.00 (0.00%)
At close: 03:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close17.00
Bid16.39 x 305200
Ask17.18 x 0
Day's range17.00 - 17.00
52-week range15.78 - 20.31
Avg. volume1,190
Market cap9.005B
Beta (5Y monthly)0.18
PE ratio (TTM)17.35
EPS (TTM)0.98
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yield0.39 (2.20%)
Ex-dividend date27 Jun 2024
1y target estN/A
  • PR Newswire

    Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC

    Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina. The 171,700-square-foot, two-reactor facility will accelerate the company's development and production of biologic therapies for patients with rare and serious diseases while also co

  • PR Newswire

    Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

    Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.

  • Business Wire

    First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome

    TOKYO, April 15, 2024--On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)", a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subt